Ketamine Injection Shortage

• • Ketalar injection, Par Pharmaceuticals, 10 mg/mL, 20 mL vial, 10 count, NDC 42023-0113-10
  • Ketalar injection, Par Pharmaceuticals, 100 mg/mL, 5 mL vial, 10 count, NDC 42023-0115-10
  • Ketalar injection, Par Pharmaceuticals, 50 mg/mL, 10 mL vial, 10 count, NDC 42023-0114-10
  • Ketamine injection, Eugia US, 10 mg/mL, 20 mL vial, 10 count, NDC 55150-0438-10
  • Ketamine injection, Eugia US, 100 mg/mL, 10 mL vial, 10 count, NDC 55150-0440-10
  • Ketamine injection, Eugia US, 50 mg/mL, 10 mL vial, 10 count, NDC 55150-0439-10
  • Ketamine injection, Hikma, 100 mg/mL, 5 mL vial, 10 count, NDC 00143-9509-10
  • Ketamine injection, Hikma, 50 mg/mL, 10 mL vial, 10 count, NDC 00143-9508-10
  • Ketamine injection, Pfizer, 100 mg/mL, 5 mL vial, 10 count, NDC 00409-2051-05
  • Ketamine injection, Pfizer, 50 mg/mL, 10 mL vial, 10 count, NDC 00409-2053-10

• • AuroMedics (Eugia) has ketamine on shortage due to increased demand.
  • Hikma has ketamine injection on back order due to shortage of active ingredient.
  • Mylan Institutional divested ketamine to AuroMedics.
  • Par has Ketalar on back order due to shortage of active ingredient.
  • Pfizer has ketamine on shortage due to manufacturing delays.
  • Sagent has ketamine injection available.

• • Ketamine injection, Sagent, 10 mg/mL, 20 mL vial, 10 count, NDC 25021-0682-20
  • Ketamine injection, Sagent, 100 mg/mL, 5 mL vial, 10 count, NDC 25021-0684-05
  • Ketamine injection, Sagent, 50 mg/mL, 10 mL vial, 10 count, NDC 25021-0683-10

Estimated Resupply Dates

• • Eugia has ketamine 50 mg/mL 10 mL vials and 100 mg/mL 10 mL vials on long-term back order and the company cannot estimate a release date. The 10 mg/mL 20 mL vials are on back order and the company cannot estimate a release date.
  • Hikma has ketamine 100 mg/mL 5 mL vials and 50 mg/mL 10 mL vials on allocation.
  • Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of January 2025. The 100 mg/mL 5 mL vials are available in limited supply.
  • Par has all Ketalar presentations on long-term back order and the company cannot estimate a release date.

Alternative Agents & Management

• • There are practice guidelines available for moderate procedural sedation and analgesia. These are available at https://pubs.asahq.org/anesthesiology/article/128/3/437/18818/Practice-Guidelines-for-Moderate-Procedural.